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Abstract
This Italian multicenter retrospective study compared the drug survival and efficacy of different
anti-TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients. A database of PsO/PsA
patients treated with adalimumab, etanercept, and infliximab from May 2013 to May 2014 was
analyzed. PASI 75, 90, and 100 was calculated at each time point to evaluate efficacy. Drug sur-
vival rate and probability of maintaining PASI response were evaluated. The impact of dependent
variables on probability of PASI 75 loss was evaluated by logistic regression. 1,235 patients were
included, 577 with PsO and 658 with PsA. Highest survival rates were observed with adalimumab
followed by etanercept and infliximab in PsO and PsA patients. The probability of maintaining
PASI response was significantly higher for adalimumab followed by infliximab. For PsO patients,
the odds of losing PASI 75 was higher in etanercept-treated patients (OR: 8.1; 95% CI: 4.2–15.6,
p< .001) or infliximab (OR: 6.6; 95% CI: 2.6–16.3, p< .001) vs. adalimumab. Likewise, for PsA
patients the odds of losing PASI 75 was higher in etanercept-treated patients (OR: 2.3; 95% CI:
1.4–3.8, p5 .01) or infliximab (OR: 2.2; 95% CI: 1.1–4.1, p5 .018) vs. adalimumab. Adalimumab
could be the best therapeutic option over other anti-TNF agents for the treatment of PsO and PsA
patients.
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1 | INTRODUCTION
Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic and invalidating
diseases affecting 1–3% and 0.16–0.25% of the world population,
respectively (Haddad & Chandran, 2012). Psoriasis is an inflammatory
skin disease requiring lifelong care; plaque psoriasis being the most
common form (90%), characterized by painful and itchy erythematous
plaques, usually covered with flaking silver scales and localized on
scalp, elbows, and knees or generalized disease across wider areas of
the body (Canadian Psoriasis Guidelines Committee, 2009;
Menter, Gottlieb, and Feldman, 2008). PsA is a chronic inflammatory
seronegative spondyloarthropathy associated with PsO (Gottlieb, Kor-
man, & Gordon, 2008; Scottish Intercollegiate Guidelines Network
(SIGN), 2010), with an estimated prevalence in PsO patients of 25–
40% (Gottlieb & Dann, 2009; Laws, Barton, and Warren, 2010). The
visible plaques of PsO have a strong impact on physical and mental
functions similar to that of other severe chronic diseases,(Rapp, Feld-
man, Exum, Fleischer, & Reboussin, 1999) with high levels of stress,
poor self-esteem, increased rates of mood disorders and detrimental
effects on social functioning, interpersonal relationships and productiv-
ity (Eghlileb, Davies, & Finlay, 2007). PsA patients may develop severe
skeletal changes in addition to cutaneous signs, with a negative impact
on function and quality of life (Gossec & Smolen, 2015). A delay in the
diagnosis of PsA that is associated with adverse long term outcome,
such as joint damages and associated disabilities; the early detection of
PsA can prevent these significant complications (Gossec & Smolen,
2015; McHugh, 2015).
Treatment strategies of severe or refractory/recalcitrant PsO/PsA
recommended by International and National Guidelines are based on
disease-modifying drugs (DMARDs), such as methotrexate and cyclo-
sporine. In cases of inadequate response, contraindication or intoler-
ance to at least one DMARD, a therapy with a biologic drug such as
tumor necrosis factor (TNF) inhibitors (adalimumab, infliximab, etaner-
cept, golimumab) or anti-interleukin therapies (ustekinumab) should be
considered (Canadian Psoriasis Guidelines Committee, 2009; Gossec &
Smolen, 2015; Gossec, Smolen, and Gaujoux-Viala, 2012; Il Tratta-
mento della Psoriasi Nell’adulto, 2013; Menter et al., 2008; NICE Clini-
cal Guideline Centre, 2012; Salvarani, Pipitone, and Marchesoni, 2011;
Scottish Intercollegiate Guidelines Network (SIGN), 2010). Further-
more, in February 2016, adalimumab was approved by the European
Medicines Agency for the treatment of moderate to severe chronic pla-
que psoriasis in adult patients who are candidates for systemic therapy
and not only after previous inadequate response/intolerance to sys-
temic DMARDs (European Medicines Agency, 2016).
TNF, a pleiotropic cytokine which regulates several inflammatory
reactions and immune functions through the control of cellular proc-
esses, plays a central role in the pathogenesis of PsO and PsA. The
over-expression of TNF is able to promote pro-inflammatory conditions
and is involved in several pathogenetic mechanisms such as the accu-
mulation of leukocytes in the inflamed skin, induction of dermal vascu-
lar changes and itching, and inflammation and joint-bone damage
(Blandizzi et al., 2014). TNF inhibitors represent effective therapeutic
options for the treatment of PsO and PsA, significantly improving signs
and symptoms and reducing the disease activity. These drugs represent
an outstanding innovation in the treatment of inflammatory immuno-
mediated diseases and an important option for modifying the natural
course and the unfavorable progression of these diseases (Blandizzi,
2013; Furst, Keystone, and Braun, 2012; Raval, Lofland, Waters, &
Piech, 2011). The anti-TNF agents adalimumab, etanercept and inflixi-
mab are indicated both in PsA and PsO (Enbrel® (Etanercept), 2015;
Humira® (Adalimumab), 2015; Remicade® (Infliximab), 2015; Sim-
poni® (Golimumab), 2015; Stelara®, (ustekinumab), 2015).
National registries provide clinical data from the real-world setting,
with the main aim to monitor long-term safety of specific treatments in
the clinical setting, but they also contain other important information
difficult to collect in clinical trials, such as drug usage, real-life long-
term effectiveness, the impact on quality of life (QoL), and related eco-
nomic issues (Armuzzi et al., 2014).
The aim of this retrospective study was to collect epidemiological
and management information on PsO/PsA patients treated with TNF
inhibitors in real life. Real life data reflect the daily clinical practice, dif-
ferently from randomized clinical trials, where stricter inclusion/exclu-
sion criteria are adopted for selecting study populations.
2 | MATERIALS AND METHODS
2.1 | Patients and study design
PSONG was a retrospective longitudinal non-interventional epidemiolog-
ical investigation performed by consulting a clinical database of PsO/PsA
patients treated with biological drugs in 6 centers of Lazio region
(Gemelli Polyclinic, Rome; “Daniele Innocenzi” Polo Pontino Dermatology
Operating Unit, “La Sapienza” University, Rome; Psoriasis Centre, “La
Sapienza” University, “Umberto I” Polyclinic, Rome; “La Sapienza”
University S. Andrea, Rome; Psoriasis Clinic ISO Centre, S. Gallicano,
Dermatology Unit, Tor Vergata Hospital, Rome) between May 2013 and
May 2014. Anti-TNF agents administered to patients included etaner-
cept, infliximab, and adalimumab at common doses (prescribed within
the EU). All biologics were administered according to product guidelines
(European Medicines Agency, 2016). Inclusion criteria included: male or
female patients diagnosed with psoriasis or psoriatic arthritis currently
being treated with an anti-TNF agent; patients18 years and patients
that have signed an informed consent form. Diagnosis of psoriasis and
psoriatic arthritis was clinical. Psoriasis was diagnosed according to the
criterion of the “rule of tens” by Finlay (BSA involved >10% or PASI
score >10 or DLQI score >10) (Finlay, 2005) and all PsA patients met
the CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria for the
classification of PsA (Taylor, Gladman, & Helliwell, 2006). The database
was designed to record demographic and anamnestic data, concomitant
diseases, current and previous biologic treatments, Psoriasis Area Sever-
ity Index (PASI) score during the observational period (visits: 0, 3 months,
6 months, 1, 2, 3, 4, 5, 6, 7, 8 years). Ethics committee approval from all
participating centers and written informed consent for the anonymous
use of personal data was obtained from every patient, in compliance
with Legislative Decree 196/2003. This study complies with the ethical
standards laid down in the 1975 Declaration of Helsinki.
2 of 9 | POTENZA ET AL.
2.2 | Outcome measures
To evaluate the efficacy of each anti-TNF agent, the response rate of a
75%, 90%, and 100% improvement in the PASI score (respectively PASI
75, PASI 90, and PASI 100) was calculated at each time point. The sur-
vival rate and probability of maintaining PASI 75, 90, and 100 responses
were evaluated for each treatment over the entire observation period.
2.3 | Statistical analysis
Data are presented as mean6 standard deviation for continuous varia-
bles, and absolute and relative frequency distribution for categorical
data. Comparisons between groups were performed by the Chi-
squared test for categorical variables and the Wilcoxon test for non-
parametric continuous variables. The survival rate for each biologic
treatment and time to losing the PASI targets (PASI 75/90/100) were
estimated by means of Kaplan-Meier survival curves. The comparison
between drug survival rates was performed using the Log-rank test.
Linear regression for repeated measures was applied to evaluate the
association between the number of patients achieving PASI 75/90/100
among the different biological drugs. All analyses were stratified
according to disease type (PsO or PsA). p< .05 was considered statisti-
cally significant. All analysis was performed using SAS version 8.2 for
Windows or Stata 12.
3 | RESULTS
3.1 | Baseline demographic and clinical characteristics
A total of 1,235 patients were included in the PSONG study, 577 in
the PsO group and 658 in the PsA group. Patient clinical and demo-
graphic characteristics are presented in Supporting Information
Table S1. There were a higher proportion of male patients in both the
PsO (71.3%) and PsA (57.1%) groups. PsA patients were slightly older
(55 vs. 50 years) and PASI score was higher in PsO patients (range 11–
18 vs. 4–14). Clinical characteristics prior to initial anti-TNF treatment
were well matched across groups (Supporting Information Table S1).
3.2 | Probability of maintaining treatment
In PsO patients the probability of maintaining treatment over the 8-
year follow-up period was highest in those treated with adalimumab
compared to those treated with etanercept (p5 .061) or infliximab
(p< .001) (Figure 1a). At 6 years, the probability of maintaining adali-
mumab treatment (0.62; 95%CI: 0.52–0.7) was approximately 10%
higher than etanercept (0.49; 95% CI: 0.42–0.56) and about 30%
higher than infliximab (0.33; 95% CI: 0.21–0.44).
In PsA patients, although patients treated with etanercept had a
similar probability of maintaining treatment compared to adalimumab at
2 years (0.76; 95% CI: 0.72–0.80 vs. 0.74; 95% CI: 0.68–0.79, respec-
tively), adalimumab-treated patients had higher probability of maintain-
ing treatment for the remainder of the follow-up period (Figure 1b). As
expected, no statistically significant difference was noted between the
probability of maintaining treatment for these 2 groups (p5 .91), over
the entire follow-up period however, infliximab treated patients
revealed significantly lower probability of maintaining treatment com-
pared to adalimumab (p< .001) and etanercept (p< .001).
3.3 | Probability of maintaining PASI 75, 90, and 100
The probability of the 3 different anti-TNF therapies maintaining PASI
75, 90, and 100 for PsO, and PsA patients are summarized in Figure 2.
PsO patients treated with adalimumab had a significantly higher proba-
bility of maintaining PASI 75, 90, and 100 compared to etanercept or
infliximab (Figure 2a–c). The probability of maintaining PASI 75 was
higher for adalimumab compared to etanercept (p< .001) or infliximab
(p5 .05) (Figure 2a). Similarly, adalimumab was more effective in
maintaining PASI 90 compared to etanercept (p< .01) or infliximab
(p5 .002) (Figure 2b). This trend was also observed for PASI 100, where
adalimumab was more effective compared with etanercept (p< .01) or
infliximab (p< .01) (Figure 2c). The magnitude of the difference
between adalimumab can be reflected in the difference in probability at
4 years compared to etanercept (0.57; 95% CI: 0.43–0.69 vs. 0.098;
95% CI: 0.04–0.20). In PsA patients, apart from PASI 75 (Figure 2d),
adalimumab was superior in maintaining PASI 90 and 100 compared to
etanercept or infliximab. For maintenance of PASI 90, adalimumab was
more effective compared with etanercept (p5 .044) or infliximab
(p5 .024) (Figure 2e). This difference was also maintained for PASI 100
FIGURE 1 Drug survival rates of 3 different anti-TNF agents in
PsO and Psa patients
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where a statistically significant difference was observed between adali-
mumab and etanercept (p5 .050) or infliximab (p< .01) (Figure 2f).
3.4 | PASI clinical response rate
The clinical response was evaluated as the rate of patients attaining
PASI 75, 90, or 100 over the 7 year follow up period. Figure 3 shows
the rate of PsO and PsA patients with PASI 75, 90, and 100 response
stratified by anti-TNF treatment. The proportion of PsO patients with
PASI 75 over the follow up period was higher for adalimumab vs.
etanercept and infliximab (Figure 3a). Similarly, a higher proportion of
patients attained PASI 90 treated with adalimumab compared to
etanercept or infliximab as well as those patients with PASI 100
(Figure 3b,c). In contrast, in PsA patients, no differences in terms of
PASI 75 response rate were observed among the three treatments
(Figure 3d). PASI 90 and PASI 100 responses were markedly higher in
patients treated with adalimumab compared with patients treated with
etanercept (Figure 3e,f). A higher PASI 100 response rate was observed
for adalimumab vs. infliximab (Figure 3f).
3.5 | Impact of predictor variables on PASI 75 loss
Logistic regression analysis was used to evaluate the impact of
independent variables on the probability of PASI 75 loss in the PsO
FIGURE 2 Probability of maintaining PASI 75, 90 and 100 in PsO and PsA patients
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and PsA groups (Supporting Information Table S2, upper panel). In
PsO patients, univariate analysis revealed that etanercept and inflixi-
mab compared to adalimumab treatment increased the odds of PASI
loss by 8.9- (95% CI: 14.7–16.9) and 6.6-fold (95% CI: 2.78-15.7),
respectively. The presence of 1 or>1 previous therapies were asso-
ciated with a protective effect against PASI 75 loss as was baseline
PASI, where every 1 unit increase in baseline PASI was associated
with a 5% reduction in odds of PASI 75 loss. Multivariate logistic
analysis was performed excluding variables that had a p value .2
following univariate analysis. In addition to baseline PASI having a
protective effect on PASI 75 loss, etanercept (Odds ratio: 8.1, 95%
CI: 4.2–15.6, p< .001) and infliximab (Odds ratio: 6.6, 95% CI: 2.6–
16.3, p< .001) compared to adalimumab treatment still emerged as
strong predictors of PASI 75 loss. The effect of biologic therapy had
less of an impact on PASI 75 loss in PsA patients (Supporting
Information Table S2, lower panel). Univariate analysis showed that
etanercept and infliximab compared to adalimumab treatment
increased the odds of PASI 75 loss by 2.33- (95% CI: 1.4–3.8,
p5 .001) and 2.32-fold (95% CI: 1.14–4.1, p5 .01), respectively.
Baseline PASI was not associated with PASI 75 loss. Etanercept
(Odds ratio: 2.29, 95% CI: 1.4–3.77, p5 .001) and infliximab (Odds
ratio: 2.19, 95% CI: 1.14–4.14, p5 .018) compared to adalimumab
treatment still emerged as significant predictors of PASI 75 loss
following multivariate logistic analysis.
4 | DISCUSSION
The main outcome measure examined in this retrospective study, car-
ried out in a routine clinical setting using the data of a clinical database
of PsO/PsA patients treated with biological drugs in 6 Italian centers,
FIGURE 3 PASI clinical response rate in PsO and PsA patients
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was the drug survival, which reflects a drug’s effectiveness, safety and
tolerability. Drug survival is based on several factors such as dosage,
effectiveness, improvement of the quality of life, safety and compliance
and could be considered an overall marker for treatment success.
Gisondi et al. recently demonstrated that the retention rate (the
number of patients who maintain the same therapy during a given
period of treatment) of TNF-alpha inhibitors was significantly higher
compared with conventional systemic treatment (DMARDs), due to a
better tolerability (Gisondi, Tessari, Di Mercurio, Del Giglio, & Girolo-
moni, 2013). In fact, the number of patients who discontinued TNF-
alpha inhibitors was lower than that of DMARDs. No differences were
noted among TNF-alpha inhibitors (Gisondi, Tessari, & Di Mercurio,
2013). An Italian experience (BEETLE study) evaluated 1,219 patients
included in administrative databases of five Italian local health units
(LHU) in Emilia-Romagna, Lazio, Tuscany, Campania, and Lombardy.
Patients were affected by rheumatoid arthritis (36%), PsO (31%),
Crohn’s disease (10%) and other immune-mediated inflammatory
diseases and treated with etanercept (n5615), adalimumab (n5420),
and infliximab (n5184). Among the group of patients who did not
switch to another drug (94%), the rate of adherence across all indica-
tions was higher for infliximab (51%) compared to etanercept (27%) or
adalimumab (23%) (Degli Esposti, Sangiorgi, & Perrone, 2014).
Our results show that in PsO patients, adalimumab has the highest
survival rate, statistically superior to that of etanercept and infliximab.
These results are partially in contrast with other recent epidemiological
surveys (Esposito, Gisondi, & Cassano, 2013; Gniadecki, Kragballe,
Dam, & Skov, 2011; Gniadecki, Bang, and Bryld, 2015).
The retrospective study Outcome and Survival Rate Concerning
Anti-TNF Routine treatment (OSCAR) showed that etanercept had a
longer survival (mean 51.4 months, p< .001) compared with infliximab
(36.8 months) and adalimumab (34.7 months) (Esposito et al., 2013).
Gniadecki et al. evaluated the data of the Danish prospective nation-
wide database DERMBIO (registry for PsO patients showing that in the
group of anti-TNF-a-naive patients, the longest drug survival was
observed for infliximab, followed by adalimumab and etanercept
(Gniadecki, Kragballe, & Dam, 2011). A recently published update of
this study included 1,867 treatment series over a period of 10 years. In
this study, drug survival was significantly longer for ustekinumab than
for the anti-TNF-alpha inhibitors (p< .001). In particular, adalimumab
and infliximab had comparable median survival rates and etanercept
had the shortest survival time (Gniadecki et al., 2015).
Our data confirmed previously reported data from several registry-
based studies (Brunasso, Puntoni, & Massone, 2012; Iskandar, et al.
2015May18; Menting, Sitaram, & Bonnerjee-van der Stok, 2014; van
den Reek et al., 2014; Warren et al., 2015). In a retrospective cohort
study evaluating tolerability and safety of biological drugs (adalimumab,
efalizumab, etanercept, and infliximab) in 108 PsO patients infliximab
was significantly associated with a shorter adherence to therapy com-
pared with adalimumab, etanercept, and efalizumab (Brunasso et al.,
2012). The British Association of Dermatologists Biologic Interventions
Register (BADBIR) is a prospective, observational database designed to
evaluate the long-term safety of biologic and conventional systemic
treatments for adults with moderate-to-severe PsO in the U.K. and
Republic of Ireland. 5,065 (60%) out of 8,399 patients included in BAD-
BIR received a biologic drug: 52.8% adalimumab, 24.6% etanercept,
18.7% ustekinumab, and 3.9% infliximab (Iskandar et al., 2015). Warren
et al. calculated the survival rates of the first course of biologics for
3523 biologic-naïve patients with chronic plaque PsO enrolled in
BADBIR database. The overall survival rate in the first year was 77%
and 53% in the third year. In particular, patients treated with etanercept
or infliximab were more likely to discontinue therapy compared with
adalimumab or ustekinumab (Warren et al., 2015). Similar results were
observed in Bio-CAPTURE (Continuous Assessment of Psoriasis
Treatment Use Registry with biologics) registry, implemented by the
department of Dermatology of the Radboud University Medical Center,
Nijmegen in 2005. The results of these trials showed that the 1-year
drug survival rates for ustekinumab, adalimumab, and etanercept were
85%, 74%, and 68%, respectively (van den Reek et al., 2014). Finally, a
single center database analysis performed in the Academic Medical
Center, Amsterdam, the Netherlands, on 221 PsO patients treated with
biological drugs showed no statistically significant differences in terms of
drug survival, either in naive episodes (etanercept 82–52%, adalimumab
75–80%, infliximab 73–57% after year 1–4), or in non-naive episodes
(etanercept 77–31%, adalimumab 75–44%, infliximab 65–43% after
year 1–4, ustekinumab 80–25% after year 1–3) (Menting et al., 2014).
According to our data, in PsA patients the probability of remaining
in treatment was higher for adalimumab, significantly lower for etaner-
cept, followed by infliximab. Our findings contrast with those in other
reports. The retrospective study by Fabbroni et al. evaluated treatment
persistence rates and causes of discontinuation in 268 PsA and anky-
losing spondylitis patients treated with biological drugs in clinical prac-
tice (Fabbroni, Cantarini, & Caso, 2014). The comparison among the 3
anti-TNF drugs showed a difference in terms of drug survival: a with-
drawal was required in 28.9% of patients treated with adalimumab,
22.8% of patients treated with etanercept and in 38.2% of those
treated with infliximab; the difference between etanercept and inflixi-
mab was statistically significant (p5 .0058) (Fabbroni et al., 2014). An
epidemiological observational cohort study from The Danish biologics
registry DANBIO evaluated the patients’ clinical response and drug sur-
vival to anti-TNF-alpha inhibitors of 764 PsA patients (Glintborg,
Østergaard, & Dreyer, 2011). The results showed that the median drug
survival was 2.9 years, and 1-year and 2-year drug survival rates were
70% and 57%, respectively. In particular, no differences were observed
in terms of retention rates, which were similar among patients receiving
infliximab, adalimumab and etanercept (Glintborg et al., 2011).
Considering the efficacy outcome based on PASI response and the
survival rate, in our experience adalimumab was the most effective treat-
ment both in PsO and in PsA patients. These efficacy results are similar
to or even higher than those reported in clinical trials (Armesto,
Coto-Segura, Mayorga, Illaro, & Santo-Juanes, 2015; Esposito, Giunta,
and Mazzotta, 2012; Gordon et al., 2012; Lopez-Ferrer, Vilarrasa, Gich,
& Puig, 2013; Menter et al., 2008; Papp, Ho, and Teixeira, 2012; Papp,
et al. 2009September–October). Some recent meta-analyses and direct/
indirect comparisons evaluated the effectiveness of available biological
drugs in PsO and PsA patients. Overall, the results showed that there
were no significant differences between the drugs in relation to the
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efficacy outcomes, except for a superiority of ustekinumab, adalimumab
and infliximab versus etanercept in terms of PASI response in PsO
patients (Galvan-Banqueri, Marín Gil, Santos Ramos, & Bautista Paloma,
2013; Puig, Lopez, Vilarrasa, & García, 2014; Reich, Burden, Eaton, &
Hawkins, 2012; Schmitt, Rosumeck, and Thomaschewski, 2014).
Taken together, these results confirm that adalimumab is a valid
therapeutic options for the long term management of severe-to-
moderate PsO and PsA patients, as recommended by International and
National guidelines. Furthermore, adalimumab is the only anti-TNF
agent approved for first line treatment of moderate to severe chronic
plaque psoriasis in adult patients (16). It is noteworthy that biological
drugs are often combined with traditional therapies in daily clinical
practice: this aspect should be further evaluated in clinical trials, as well
as the clinical response in PsO and PsA biologic experienced vs. naïve
patients.
4.1 | Study strengths and limitations
This study is of particular value as it provides longitudinal data
(collected retrospectively) from 1,235 patients, (577 in the PsO group
and 658 in the PsA group) from 6 centers with follow-up times rang-
ing from 6 months to 8 years. To date, few studies are available that
report data on this Italian population. However, there are some
potential limitations that need to be addressed. Weaknesses of obser-
vational registries such as the reliability of results and incompleteness
of data have previously been highlighted (Vandenbroucke, von Elm,
and Altman, 2007; von Elm, Altman, and Egger, 2007). Furthermore,
the lack of randomization may also introduce selection bias, and the
presence of unmeasured confounders cannot always be ruled out.
However, we did not observe any marked changes in clinical charac-
teristics among treatment groups attributed to loss during follow-up.
This potential limitation was also addressed by including potential
confounding variables in logistic regression models. It is recognized
that efficacy and retention in therapy for biologics is correlated with
line of treatment. Although the proportion of naive patients was not
markedly different in the PsO (50–65%) and PsA groups (30–55%),
our analysis did not specifically examine efficacy by line of treatment,
which was not feasible due to the low sample sizes for this sub-
analysis. Last, our analysis was limited to the comparison of
adalimumab, etanercept, and infliximab for the treatment of PsO and
PsA patients. Few patients were treated with golimumab (N547) to
permit further analysis and certolizumab was not available in Italy at
the time this study was undertaken.
5 | CONCLUSIONS
Real-life data, typically collected by national registers and non-
interventional studies, represent an important source of information on
long-term treatment, efficacy and safety in day-to-day conditions of
clinical practice and among heterogeneous groups of patients, such as
elderly subjects or patients with comorbidities or co-medications, usu-
ally excluded from randomized controlled trials.
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